Abstract
Urinary incontinence (UI) is defined by the International Continence Society as “a complaint of any involuntary loss of urine.” It is an extremely common condition with a suggested prevalence of more than one in three adults over the age of 40 years, having clinically significant symptoms. The condition worsens with increasing age, causing significant distress, besides having a negative impact on the patients’ quality of life through a loss of dignity and an imposition of limitations on lifestyles. Despite this, UI is very much under-reported because of the perceived antisocial and embarrassing nature of this complaint. This may have considerable financial implications, and The Continence Foundation has estimated a total cost of more than £420 million for the United Kingdom (UK) (approximately 1/120th of the total expenditure of the NHS).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326(7394):841–844
Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48(1):5–26
Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun C, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) for the STAR study group. a comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48(3):464–470
Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF (2005) Botox detrusor hyperreflexia study team. botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174(1):196–200
Ahmed HU, Shergill IS, Arya M, Shah PJ (2006) Management of detrusor-external sphincter dyssynergia. Nat Clin Pract Urol 3(7):368–380
Dmochowski RR, Sand PK, Zinner NR et al (2003) Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237–242
Davila GW, Sand PK, Gonick CW, Parker RL, Dahl NV (2006) Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from the MATRIX study. Obstet Gynecol 107:S76
Lucente VR, Goldberg RP, Davila GW, Gonick CW, Parker RL, Dahl NV (2006) Impact of transdermal oxybutynin on quality of life in patients with overactive bladder: results from the MATRIX study. Obstet Gynecol 107:176
Ghoniem GM, Van Leeuwen JS, Elser DM et al (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173(5):1647–1653
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London
About this chapter
Cite this chapter
Kalsi, V., Chowdhury, A., Mammen, K. (2010). Overactive Bladder and Incontinence. In: Shergill, I., Arya, M., Grange, P., Mundy, A. (eds) Medical Therapy in Urology. Springer, London. https://doi.org/10.1007/978-1-84882-704-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-84882-704-2_7
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-703-5
Online ISBN: 978-1-84882-704-2
eBook Packages: MedicineMedicine (R0)